| Literature DB >> 28469408 |
Usman Sumo Friend Tambunan1, Mochammad Arfin Fardiansyah Nasution1, Fauziah Azhima1, Arli Aditya Parikesit1, Erwin Prasetya Toepak1, Syarifuddin Idrus2, Djati Kerami3.
Abstract
Dengue fever is still a major threat worldwide, approximately threatening two-fifths of the world's population in tropical and subtropical countries. Nonstructural protein 5 (NS5) methyltransferase enzyme plays a vital role in the process of messenger RNA capping of dengue by transferring methyl groups from S-adenosyl-l-methionine to N7 atom of the guanine bases of RNA and the RNA ribose group of 2'OH, resulting in S-adenosyl-l-homocysteine (SAH). The modification of SAH compound was screened using molecular docking and molecular dynamics simulation, along with computational ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) test. The 2 simulations were performed using Molecular Operating Environment (MOE) 2008.10 software, whereas the ADME-Tox test was performed using various software. The modification of SAH compound was done using several functional groups that possess different polarities and properties, resulting in 3460 ligands to be docked. After conducting docking simulation, we earned 3 best ligands (SAH-M331, SAH-M2696, and SAH-M1356) based on ΔGbinding and molecular interactions, which show better results than the standard ligands. Moreover, the results of molecular dynamics simulation show that the best ligands are still able to maintain the active site residue interaction with the binding site until the end of the simulation. After a series of molecular docking and molecular dynamics simulation were performed, we concluded that SAH-M1356 ligand is the most potential SAH-based compound to inhibit NS5 methyltransferase enzyme for treating dengue fever.Entities:
Keywords: NS5 methyltransferase; S-adenosyl-l-homocysteine (SAH); dengue virus (DENV); drug design; molecular docking; molecular dynamics
Year: 2017 PMID: 28469408 PMCID: PMC5404899 DOI: 10.1177/1177392817701726
Source DB: PubMed Journal: Drug Target Insights ISSN: 1177-3928
Figure 1.The 3-dimensional structure of NS5 methyltransferase enzyme (Protein Data Bank ID: 2P41) and the S-adenosylmethionine/S-adenosyl-l-homocysteine-binding site.
Figure 2.The place of functional group modification of S-adenosyl-l-homocysteine; the modification was conducted by changing the respective functional group into another, such as alcohol, carboxylic acid, and amine, resulting in 3460 ligands in the process.
ΔGbinding and pKi value from the docking results.
| Ligand | ΔGbinding (kcal/mol) | pKi |
|---|---|---|
| SAH-M331 | −25.6660 | 18.6972 |
| SAH-M2696 | −22.3764 | 16.3008 |
| SAH-M1356 | −21.0147 | 15.3088 |
| SAH[ | −17.5047 | 13.0172 |
| SAM[ | −17.8713 | 13.0189 |
| CTWYC[ | −20.6330 | 15.0317 |
Abbreviations: SAH, S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine.
Standard ligand.
Figure 3.The chemical structures of the standards and the best ligands from molecular docking simulation.
Ligand interaction with the SAM-binding site of NS5 methyltransferase enzyme.
| Ligand | Hydrogen bond interaction site |
|---|---|
| SAH-M331 | Trp87, Asp146, Lys105, Lys181 |
| SAH-M2696 | Asp146, Lys181, Lys61, Trp87, Gly81 |
| SAH-M1356 | Lys105, His110, Glu149, Lys61, Asp146 |
| SAH[ | Arg160, Lys105, Glu149 |
| SAM[ | Asp 146, Lys 61, Glu111, His110 |
| CTWYC[ | Lys181, Asp146, Lys61, Arg57 |
Abbreviations: SAH, S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine.
Standard ligand. Red color indicates the active site of NS5 methyltransferase enzyme contact.
Figure 4.Molecular interaction and 3-dimensional visualization of binding site of SAH-based ligands, namely, SAH-M331 (top), SAH-M2696 (middle), and SAH-M1356 (bottom). SAH indicates S-adenosyl-l-homocysteine.
Figure 5.Molecular interaction and 3-dimensional visualization of binding site of standard ligands, namely, SAH (top), SAM (middle), and CTWYC (bottom). SAH indicates S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine.
The absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) property prediction by ADME-Tox software.
| Parameters/ligands | SAH-M331 | SAH-M2696 | SAH-M1356 | SAH[ | SAM[ | CTWYC[ |
|---|---|---|---|---|---|---|
| Oral bioavailability | Less than 30% | Less than 30% | Less than 30% | Less than 30% | Less than 30% | Less than 30% |
| Passive absorption | Poor | Poor | Poor | Poor | Poor | Poor |
|
| ||||||
| Blood | 0.78 | 0.83 | 0.67 | 0.79 | 0.10 | 0.99 |
| Cardiovascular | 0.01 | 0.39 | 0.21 | 0.37 | 0.48 | 0.67 |
| Gastrointestinal | 0.93 | 0.70 | 0.78 | 0.99 | 0.98 | 0.76 |
| Kidney | 0.69 | 0.79 | 0.16 | 0.23 | 0.81 | 0.89 |
| Liver | 0.74 | 0.58 | 0.58 | 0.66 | 0.83 | 1 |
| Lungs | 0.59 | 0.39 | 0.12 | 0.18 | 0.51 | 0.07 |
|
| ||||||
|
| Not transported | Not transported | Not transported | Not transported | Not transported | Not transported |
|
| Not transported | Not transported | Not transported | Not transported | Not transported | Not transported |
Abbreviations: SAH, S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine.
Standard ligand.
Carcinogenicity and mutagenicity prediction by Toxtree software.
| Parameters/ligands | SAH-M331 | SAH-M2696 | SAH-M1356 | SAH[ | SAM[ | CTWYC[ |
|---|---|---|---|---|---|---|
| Negative for genotoxic carcinogenicity | No | No | Yes | No | Yes | Yes |
| Negative for nongenotoxic carcinogenicity | Yes | Yes | Yes | Yes | Yes | Yes |
| Potential | No | No | No | No | No | No |
| Potential carcinogen based on QSAR | No | No | No | No | No | No |
Abbreviations: SAH, S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine; QSAR, quantitative structure activity relationship.
Standard ligand.
Druglikeness property prediction by OSIRIS Property Explorer software.
| Parameters/ligands | SAH-M331 | SAH-M2696 | SAH-M1356 | SAH[ | SAM[ | CTWYC[ |
|---|---|---|---|---|---|---|
| Mutagenic | No | No | No | No | No | No |
| Tumorigenic | No | No | No | No | No | No |
| Irritant | Low | No | No | No | No | No |
| Reproductive effect | No | No | No | No | No | No |
| Druglikeness | −1.12 | 0.89 | −4.91 | −7.18 | −7.41 | −1.8 |
| Drug score | 0.42 | 0.74 | 0.42 | 0.43 | 0.41 | 0.27 |
Abbreviations: SAH, S-adenosyl-l-homocysteine; SAM, S-adenosylmethionine.
Standard ligand. Red color indicates the unfavorable drug properties of a compound.
Synthetic accessibility prediction of the selected ligands.
| Parameters/ligands | SAH-M331 | SAH-M2696 | SAH-M1356 |
|---|---|---|---|
| Synthetic accessibility | 38% | 58% | 42% |
| Residual complexity | 56% | 36% | 53% |
| Starting materials | 3% | 42% | 23% |
Abbreviation: SAH, S-adenosyl-l-homocysteine.
This test was done using Computer-Assisted Estimation of Synthetic Accessibility software.
Figure 6.The RMSD curve of SAH-M331 ligand complex (top), SAH-M2696 (middle), and SAH-M1356 (bottom). RMSD indicates root-mean-square deviation; SAH, S-adenosyl-l-homocysteine.
Comparison of molecular interaction before (after docking) and after dynamics simulation.
| Simulation time/ligands | SAH-M331 | SAH-M2696 | SAH-M1356 |
|---|---|---|---|
| Docking simulation | Trp87, Asp146, Lys105, Lys181, Asp146 | Asp146, Lys181, Lys61, Asp146, Trp87, Gly81, Asp146, Trp87 | Lys105, His110, Glu149, Lys61, Asp146 |
| Molecular dynamics simulation (310 K) | Asp79, Asp79, Gly81, Gly81, Asp146, Asp146, Asp146, Arg57, Lys61, Arg160, Lys181, Tyr219, Asp146, Asp146, His110, Trp87, Trp87, Trp87 | Asp79, Asp79, Asp79, Leu80, Glu111, Asp146, Asp146, Asp146, Glu149, Glu149, Lys61, Trp87, Lys181, Asp79, Glu111, Asp146, Asp146, Lys61, Trp87 | Asp146, Gly148, Lys42, Arg57, Arg57, Lys61, Trp87, His110, Arg163, Arg163, Lys181 |
| Molecular dynamics simulation (312 K) | Gly81, Glu111, Asp146, Asp146, Asp146, Gly148, Lys105, Lys105, Arg160, Arg163, Arg163, Asp146, Glu149, Trp87, Arg163 | Ser59, Asp79, Gly106, Glu111, Glu111, Leu144, Asp146, Asp 46, Asp146, Lys22, His110, Asp146, Lys22 | Glu111, Asp146, Gly148, Arg163, Arg163, Arg212, Arg212, Lys105 |
Abbreviation: SAH, S-adenosyl-l-homocysteine.
Red color indicates the active site of NS5 methyltransferase enzyme contact.
Figure 7.Molecular interaction and 2-dimensional visualization of SAH-based ligands after molecular dynamics simulation at 310 K (left side) and 312 K (right side), namely, SAH-M331 (top), SAH-M2696 (middle), and SAH-M1356 (bottom). SAH indicates S-adenosyl-l-homocysteine.